- Home
- ODD vs PTCT Comparison
ODD vs PTCT Comparison
Compare ODD & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ODD | PTCT |
|---|---|---|
| Founded | 2018 | 1998 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 5.3B |
| IPO Year | 2023 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ODD | PTCT |
|---|---|---|
| Price | $45.11 | $77.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 17 |
| Target Price | $70.18 | ★ $73.76 |
| AVG Volume (30 Days) | 1.2M | ★ 2.3M |
| Earning Date | 11-19-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.01 | N/A |
| EPS | 1.79 | ★ 8.94 |
| Revenue | $780,758,000.00 | ★ $1,779,150,000.00 |
| Revenue This Year | $26.16 | $128.32 |
| Revenue Next Year | $20.37 | N/A |
| P/E Ratio | $25.28 | ★ $8.64 |
| Revenue Growth | 25.80 | ★ 97.54 |
| 52 Week Low | $35.30 | $35.95 |
| 52 Week High | $79.18 | $87.50 |
Technical Indicators
Market Signals| Indicator | ODD | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 56.84 | 54.29 |
| Support Level | $41.36 | $73.03 |
| Resistance Level | $44.37 | $79.03 |
| Average True Range (ATR) | 2.34 | 3.38 |
| MACD | 1.18 | -0.70 |
| Stochastic Oscillator | 89.52 | 29.37 |
Price Performance
Historical ComparisonAbout ODD ODDITY Tech Ltd.
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage.
About PTCT PTC Therapeutics Inc.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.